

17 June 2022

## NOTICE TO RELEVANT STAKEHOLDERS

Dear Sir/Ma'am:

This refers to the draft regulations distributed through the World Trade Organization – Technical Barriers to Trade (WTO-TBT) website ([www.tbts.wto.org](http://www.tbts.wto.org)) from 28 May to 03 June 2022.

Relative thereto, we respectfully invite stakeholders to comment on the six (6) notified draft technical regulations from six (6) WTO Member Countries:

| Document Symbol                         | Notifying Member  | Relevant Dates  | Products Covered   | Summary   |
|---|-------------------|---|--|---|
| <a href="#">G/TBT/N/BRA/1330/Corr.1</a> | Brazil            | <b>Date of Distribution:</b><br>02 June 2022<br><br><b>Deadline for Comments:</b><br>Not Applicable | Medical devices and in vitro diagnostic products - Corrigendum | The article 3 <sup>o</sup> of the Resolution - RDC number 665, 30 March 2022 - previously notified through G/TBT/N/BRA/1330 - which incorporates into the national legal system the Resolution of MERCOSUR (GMC) number 20, 17 November 2011, MERCOSUR/GMC/RES. n <sup>o</sup> 20/11, "MERCOSUR Technical Regulation on Good Manufacturing Practices for Medical Devices and In Vitro Diagnostic Products". |
| <a href="#">G/TBT/N/CHL/595</a>         | Chile             | <b>Date of Distribution:</b><br>31 May 2022<br><br><b>Deadline for Comments:</b><br>30 July 2022    | Pharmaceutical products : oral contraceptives                  | The notified Exempt Resolution establishes requirements for oral contraceptives consisting of active and placebo tablets.   |
| <a href="#">G/TBT/N/KOR/1076</a>        | Republic of Korea | <b>Date of Distribution:</b><br>31 May 2022<br><br><b>Deadline for Comments:</b><br>20 June 2022    | Quasi-drug   | MFDS is amending the "Korean Quasi-drug Codex" as follows: 1) Improve the identification test for "Benzalconium Chloride"; 2) Establish a purity test method for Benzene in "Carbomers", etc.   |
| <a href="#">G/TBT/N/MEX/495/Add.2</a>   | Mexico            | <b>Date of Distribution:</b><br>31 May 2022<br><br><b>Deadline for Comments:</b><br>Not Applicable  | Nutritional and medicinal sterile mixtures - Addendum          | Amendments have been made to points 5.2, 5.3, 5.4, 5.5, 5.6, 5.6.5, 6.1, 7.11.3, 8.1, 11.8.1.3, 11.23; 20.3 and to points 5.3, 5.4, 5.6.5, 7.11.3, 11.22, 11.23 y 20.3 of Regulatory Appendix A of Mexican Official Standard NOM-   |

**BUREAU OF PHILIPPINE STANDARDS**



3F Trade and Industry Building, 361 Sen. Gil Puyat Avenue  
1200 Makati City, Philippines  
(+632) 791.3124, 751.3126  
[bps@dti.gov.ph](mailto:bps@dti.gov.ph)



(+632) 751.4700  
[www.bps.dti.gov.ph](http://www.bps.dti.gov.ph)

### Membership:

International Organization for Standardization (ISO)  
International Electrotechnical Commission (IEC)  
World Trade Organization (WTO) Technical Barriers to Trade (TBT)  
- National Enquiry Point (NEP) - National Notification Authority (NNA)

|                                  |             |   |   |  |
|----------------------------------|-------------|---|---|--|
|                                  |             |   |   | 249-SSA1-2010, Nutritional and medicinal sterile mixtures, and equipment for the preparation thereof, published in the Official Journal on 4 March 2011  |
| <a href="#">G/TBT/N/PE R/143</a> | Peru        | <b>Date of Distribution:</b><br>31 May 2022<br><br><b>Deadline for Comments:</b><br>30 July 2022  | Medicinal and therapeutic use of cannabis and its derivatives | The purpose of the notified text is to regulate: 1) The provisions established in Law No. 30681, Law regulating the medicinal and therapeutic use of cannabis and its derivatives, and Law No. 31312 amending it, to ensure the medicinal and therapeutic use of cannabis and its derivatives; 2) Access to cannabis and its derivatives exclusively for medicinal and therapeutic purposes, promoting their rational use. |
| <a href="#">G/TBT/N/PH L/289</a> | Philippines | <b>Date of Distribution:</b><br>01 June 2022<br><br><b>Deadline for Comments:</b><br>03 June 2022 | Investigational products used in clinical trials              | The proposed issuance aims to provide guidelines on reliance for approval of clinical trials and to promote a more efficient and effective approach to the regulations in the oversight of the conduct of clinical trials in the Philippines.  |

To access the notification form, right click the document symbol to open the hyperlink. Should you have any queries on this matter or request for full text of draft regulation in English, please do not hesitate to email us at [BPS@dti.gov.ph](mailto:BPS@dti.gov.ph), copy Mrs. Catherine Antonio-Paguinto ([CatherineAntonio@dti.gov.ph](mailto:CatherineAntonio@dti.gov.ph)) and Ms. Jasmin E. Metre ([JasminMetre@dti.gov.ph](mailto:JasminMetre@dti.gov.ph)).

Thank you.

Sincerely,

**NEIL P. CATAJAY**  
Director